ClinicalTrials.gg
DrugRead study by study

Datopotamab deruxtecan clinical trials

Also written Dato-DXd and DS-1062a.

studies test it
38
open now
18
in phase 3
17
first study started
2010
ClinicalTrials.gov finds 50 studies for datopotamab deruxtecan. How that becomes 38 here

Every study that search finds has been read, to see whether and how it gives datopotamab deruxtecan. ClinicalTrials.gov counts as of Nov 16, 2026. How drug pages count

  1. 50Found by its intervention search · See all 50 hereIt also reads titles, arm labels, keywords and descriptions, and counts the drug’s other names. Of these, 41 name it in an intervention entry. The counts it shows beside each synonym overlap: a study writing two names counts under both.
  2. +3Give it under a name that search misses: a biosimilar’s code or a misspelling
  3. 53Give datopotamab deruxtecan to participants
  4. −3Observe patients on it, or give it outside a trial
  5. −12Give it beside what is tested
  6. 38Test it: the count on this site

Get an email when these change. Save the datopotamab deruxtecan studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
17 Jan 2025 · DATROWAY · BLA 761394 (FDA, Drugs@FDA)
European Union
4 Apr 2025 · Datroway · EMEA/H/C/006547 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Datopotamab deruxtecan
20
Datopotamab deruxtecan (Dato-DXd)
6
Datopotamab deruxtecan (Dato-DXd, DS-1062a)
5
Dato-DXd, DS-1062a
3

Brand

DATROWAY®
1

Development codes

Dato-DXd
21
DS-1062a
11
DS-1062
2

Studies by the year they started

38 studies that test it; most in 2022 (7)

Studies that test datopotamab deruxtecan, by start year
YearStudies
20101
20182
20191
20202
20214
20227
20234
20247
20256
20264

By phase

A phase 1/2 study counts in both.

Phase 1
7
Phase 2
19
Phase 3
17

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 28 · Other 10

AstraZeneca (20) · Daiichi Sankyo (7) · Gustave Roussy, Cancer Campus, Grand Paris (2) · Medical University of Vienna (1) · Daiichi Sankyo Co., Ltd. (1) · Fudan University (1) · UNC Lineberger Comprehensive Cancer Center (1) · Ana C Garrido-Castro, MD (1)

Often tested with

Tested in the same studies.

Carboplatin (6) · Durvalumab (5) · Rilvegostomig (5) · Cisplatin (4) · Trastuzumab deruxtecan (3) · Pemetrexed (3) · Ado-Trastuzumab Emtansine (2) · Pembrolizumab (2)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

New treatments tested with it · 5 most studied

New when their studies opened, with datopotamab deruxtecan beside them; studies of each.

Reaching primary completion within a year · 6, 4 in phase 3

Studies that test datopotamab deruxtecan, phase 3 first.

Studies

Open first, then newest update. How each study uses datopotamab deruxtecan has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Some give it without naming it in an intervention entry: those were found by reading the record.

Testing it · 38

See all 38 studies that test datopotamab deruxtecan →

Behind its US label · 4 — the studies the FDA label of DATROWAY describes

From the Clinical Studies section of DATROWAY (2026-05), as openFDA has it. A study the site does not hold is left out.

Tested on its own · 12 — no other medicine in its arm
Tested with established drugs · 9 — they are given beside it
Tested in a combination · 17 — another drug in the study is under test too
Beside an established treatment under test · 1 — an approved drug, surgery or radiation is what the study tests

Tested with datopotamab deruxtecan: durvalumab 1

Beside a new treatment under test · 7 — a new drug, cell therapy or vaccine is what the study tests

New treatments tested with datopotamab deruxtecan: AZD5305 1 · isuventatug 1 · GB268 1 · palacaparib 1 · PRMT5 Inhibitor AZD3470 1

Beside supportive care · 4 — a supportive treatment or test is studied
Observed · 3 — patients on it are followed, or it is given outside a trial

What changed recently

From the registry's own updates since Oct 18, 2026.

Codes

What other systems call datopotamab deruxtecan · ClinicalTrials.gg INT002176

  • MeSH (NLM) C000731951datopotamab deruxtecanOne source NLM
  • UNII (FDA) GD2OWY1DTKDATOPOTAMAB DERUXTECANConfirmed FDA, NLM
  • NCI Thesaurus C151967Datopotamab DeruxtecanOne source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.

Start the discussion